Innovative Digital Platform Centese's Thoraguard system leverages advanced digital and automation technology to improve patient recovery following cardiothoracic surgery, positioning it as a cutting-edge solution for hospitals seeking to modernize postoperative care.

Strong Clinical Evidence Multiple peer-reviewed clinical studies, including collaborations with Stanford University Medical Center, validate the safety and efficacy of Thoraguard, increasing its appeal to healthcare institutions prioritizing evidence-based medical devices.

Strategic Leadership Recent appointment of Timothy Still to the Board of Directors signals a focus on strengthening corporate governance and scaling growth efforts, which may open new partnership opportunities and funding channels.

Market Traction & Funding With over 1 million dollars in revenue and 15 million dollars in funding, Centese demonstrates growing market presence and financial backing, making it an attractive partner for healthcare providers and investors interested in innovative medical technology.

Growing Industry Presence The company's focus on clinical validation and continuous product development positions it well within the competitive thoracic and cardiac surgery device market, offering multiple opportunities to collaborate with hospital systems seeking outcome-driven solutions.